# A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

> **NCT06267274** · PHASE1 · RECRUITING · sponsor: **Amneal Pharmaceuticals, LLC** · enrollment: 240 (estimated)

## Conditions studied

- Open-angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Bimatoprost Ophthalmic Solution, 0.01%
- **DRUG:** LUMIGAN® (bimatoprost ophthalmic solution) 0.01%

## Key facts

- **NCT ID:** NCT06267274
- **Lead sponsor:** Amneal Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2024-08-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06267274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06267274, "A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06267274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*